Research & Development Market Research Reports & Industry Analysis

Research and development activities are the heart of the pharmaceutical industry’s value creation. R&D fuels the product pipeline but takes its fair share of the expense side of the balance sheet. It is estimated that bringing a successful drug to market from discovery through development to market launch costs well in excess of US$1 billion.

Bringing R&D costs and times down, therefore, means there are many opportunities to improve efficiencies, advance technological innovation, and economize and optimize. The pharmaceutical R&D category tracks both drug pipeline reports, competitive R&D strategies, and markets important and ancillary to the research efforts themselves, including activities in the biotech and sector that impinge upon the process.

...Show More ...Show Less


Research & Development Industry Research & Market Reports

  • Global Certified Reference Materials Market - 2023-2030

    ... quality and metrological traceability of products, validate analytical measurement methods, or calibrate instruments. Certified reference material is a particular form of measurement standard. Reference materials are essential for analytical chemistry and clinical analysis. Since most ... Read More

  • Global Organ-On-Chip Market - 2024 - 2031

    ... 2024-2031. The organ-on-chip market trends show increasing government initiatives and investment in drug development owing to the rising prevalence of oncology and increasing research and development. Organ-on-chip aims to design human tissue prototypes for disease ... Read More

  • Global Organoids Market - 2024 - 2031

    ... to replicate much of an organ's complexity or express selected aspects, like producing only certain types of cells. Organoids Market Dynamics and Trends The global organoids market is driven by technological advancements in 3D cell ... Read More

  • 2025 Biotech Research and Development Global Market Size & Growth Report with Updated Analysis & Forecasts

    ... with forecasts for 2025 and 2029. The historical data utilizes in-depth survey results from companies in the Biotech Research and Development industry combined with country and regional economic, firmographic, and demographic data. Our analysts develop ... Read More

  • Drug Discovery Technologies

    ... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More

  • Virus Filtration Products

    ... at a CAGR of 12.4% over the analysis period 2024-2030. Virus Filtration Kits & Reagents, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.8 Billion by ... Read More

  • Cold Plasma

    ... CAGR of 14.8% over the analysis period 2024-2030. Atmospheric Regime, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$3.7 Billion by the end of the analysis ... Read More

  • Peptide Synthesis

    ... CAGR of 4.3% over the analysis period 2024-2030. Peptide Synthesis Reagent, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$161.7 Million by the end of the ... Read More

  • Protein Characterization and Identification

    ... 2030, growing at a CAGR of 13.2% over the analysis period 2024-2030. Protein Characterization & Identification Consumables, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$17.2 ... Read More

  • Bone Marrow Aspirate Concentrates

    ... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Bone Marrow Aspirate Concentrates Systems, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$178.5 ... Read More

  • Asthma Therapeutics

    ... CAGR of 2.3% over the analysis period 2024-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$10.7 Billion by the end of the analysis ... Read More

  • Bioburden Testing

    ... CAGR of 11.3% over the analysis period 2024-2030. Bioburden Testing Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the ... Read More

  • In Vivo Contract Research Organization (CRO)

    ... reach US$8.0 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Smalll Molecules Modality, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and ... Read More

  • Genomics in Cancer Care

    ... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomics Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the ... Read More

  • Recombinant DNA Technology

    ... at a CAGR of 4.5% over the analysis period 2024-2030. Medical Recombinant DNA Technology, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$77.9 Billion by the ... Read More

  • Research Antibodies

    ... CAGR of 4.7% over the analysis period 2024-2030. Reagent, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$5.4 Billion by the end of the analysis period. ... Read More

  • Cancer Immunotherapy

    ... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More

  • Biobanks

    ... 7.7% over the analysis period 2024-2030. Physical / Real Biobanks, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$108.4 Billion by the end of the analysis ... Read More

  • Bone Marrow Transplant

    ... at a CAGR of 4.1% over the analysis period 2024-2030. Autologous Transplant, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$8.7 Billion by the end of ... Read More

  • Biotech Flavors

    ... CAGR of 6.7% over the analysis period 2024-2030. Vanilla & Vanillin Flavors, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$872.9 Million by the end of ... Read More

  • Hepatitis C Treatment

    ... at a CAGR of 10.7% over the analysis period 2024-2030. HCV Protease Inhibitors, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$25.3 Billion by the end ... Read More

  • Soft Tissue Allografts

    ... at a CAGR of 4.9% over the analysis period 2024-2030. Orthopedic Application, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.9 Billion by the end of ... Read More

  • Human Liver Models

    ... at a CAGR of 9.3% over the analysis period 2024-2030. Liver Organoids, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$250.6 Million by the end of ... Read More

  • Biotech Business February 2025

    ... on biotechnology products and companies. It reports which universities offer licensing of biotechnology research, which companies have entered licensing agreements, as well as the financial health of biotechnology companies and their expected growth or decline. Read More

  • Bone Morphogenetic Proteins

    ... at a CAGR of 2.4% over the analysis period 2024-2030. Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2), one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$484.6 Million ... Read More

< prev 1 2 3 4 5 6 7 8 9 10

Research Assistance

Live help

Join Alert Me Now!

Sign Up

Find out more on our blog
Cookie Settings